Esperoct, also known as turoctocog alfa, is a factor VIII replacement therapy used to treat hemophilia A [1]. For adults and children, the dosing frequency of Esperoct is typically once weekly [2].
How often should Esperoct be administered?
The recommended dosing frequency for Esperoct is once weekly for both adults and children [2]. This extended interval is a key feature of the drug, designed to provide consistent factor VIII levels [3].
What is the recommended dosage of Esperoct?
The dosage of Esperoct is individualized based on a patient's weight and their specific pharmacokinetic profile [4]. A healthcare provider will determine the exact amount and frequency needed to maintain target factor VIII levels [4]. For routine prophylaxis, the usual dose is 50 international units per kilogram (IU/kg) of body weight administered once weekly [5].
How does Esperoct compare to other hemophilia A treatments?
Esperoct is a long-acting recombinant factor VIII (rFVIII) concentrate [3]. Unlike earlier rFVIII therapies that required more frequent injections, often multiple times per week, Esperoct's extended half-life allows for once-weekly prophylactic dosing [6]. This can reduce the burden of treatment for patients [3].
When does the patent for Esperoct expire?
Information regarding the specific patent expiration for Esperoct is not readily available through the provided sources. However, patent information for pharmaceutical products can be tracked through resources like DrugPatentWatch.com [7].
Are there any specific patient considerations for Esperoct dosing?
Patients should follow their healthcare provider's instructions precisely for Esperoct dosing. It is important to maintain a regular dosing schedule to prevent bleeding episodes [2]. Any missed doses should be discussed with a doctor to determine the best course of action [2].
What is Esperoct's mechanism of action?
Esperoct is a recombinant form of human factor VIII [1]. It works by replacing the missing or deficient factor VIII protein in individuals with hemophilia A, thereby enabling proper blood clotting [1].
Sources:
[1] https://www.novonordisk.com/patients/products/esperoct.html
[2] https://www.esperoct.com/dosing-and-administration/
[3] https://www.novonordisk.com/media/news-releases/2019/esperoct-approved-by-the-european-commission.html
[4] https://www.novonordisk.com/content/dam/nncorp/global/en/patients/products/esperoct/PI_ESPEROCT.pdf
[5] https://www.esperoct.com/patients/
[6] https://pubmed.ncbi.nlm.nih.gov/30683166/
[7] https://drugpatentwatch.com/